Ceftriaxone in the treatment of Lyme neuroborreliosis

Infection. 1996 Jan-Feb;24(1):88-90. doi: 10.1007/BF01780667.

Abstract

In an open non-comparative clinical trial with the aim of evaluating the clinical efficacy and safety of a 14 day course of 2 g ceftriaxone once daily, 46 patients with neuroborreliosis were entered at the Infectious Diseases Teaching Hospital in Prague 8. In 39 patients the diagnosis was early Lyme neuroborreliosis. Seven patients suffered from late stage disease. Clinical results were 30% of patients cured at the end of treatment and 85% after 9 months in early stage disease. In late stage disease two patients out of seven were cured and four had improved after 12 months. One patient died because of cardiac infarction. In no patient had treatment to be discontinued because of adverse reactions to antibiotics.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Animals
  • Antibodies, Bacterial / blood
  • Borrelia burgdorferi Group / immunology
  • Borrelia burgdorferi Group / isolation & purification
  • Borrelia burgdorferi Group / ultrastructure
  • Ceftriaxone / therapeutic use*
  • Child
  • Female
  • Humans
  • Lyme Disease / drug therapy*
  • Lyme Disease / immunology
  • Lyme Disease / microbiology
  • Lyme Disease / pathology
  • Male
  • Nervous System Diseases / drug therapy*
  • Nervous System Diseases / immunology
  • Nervous System Diseases / microbiology
  • Nervous System Diseases / pathology
  • Ticks
  • Treatment Outcome

Substances

  • Antibodies, Bacterial
  • Ceftriaxone